Recurrent Plasma Cell Myeloma Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Withdrawn
- Recurrent Plasma Cell Myeloma
- Daratumumab
- +2 more
- Wichita, Kansas
- +3 more
2022-04-07
Apr 7, 2022N
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +33 more
- Birmingham, Alabama
- +1423 more
2022-04-06
Apr 6, 2022N
N
Recruiting
- Lymphoma
- +6 more
- Cytology Specimen Collection Procedure
- Birmingham, Alabama
- +139 more
2022-04-05
Apr 5, 2022R
Not yet recruiting
- Plasma Cell Myeloma
- +3 more
- Behavioral Intervention
- +6 more
- Buffalo, New YorkRoswell Park Cancer Institute
2022-03-28
Mar 28, 2022A
Not yet recruiting
- Multiple Myeloma
- +4 more
- Pembrolizumab
- San Francisco, CaliforniaUniversity of California, San Francisco
2022-03-23
Mar 23, 2022N
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Ixazomib Citrate
- Pevonedistat
- New Haven, Connecticut
- +8 more
2022-03-29
Mar 29, 2022F
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
- +3 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-03-14
Mar 14, 2022M
Suspended
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Dexamethasone
- +5 more
- Jacksonville, FloridaMayo Clinic in Florida
2022-03-22
Mar 22, 2022M
Recruiting
- Plasma Cell Myeloma
- +3 more
- Bone Marrow Biopsy
- +3 more
- Phoenix, Arizona
- +2 more
2022-03-22
Mar 22, 2022M
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Cyclophosphamide
- +4 more
- Scottsdale, Arizona
- +2 more
2022-03-23
Mar 23, 2022C
Active, not recruiting
- Autologous Hematopoietic Stem Cell Transplant Recipient
- +4 more
- bortezomib
- +7 more
- Duarte, CaliforniaCity of Hope
2022-03-17
Mar 17, 2022U
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +17 more
- Nivolumab
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-02-28
Feb 28, 2022U
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +3 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-02-28
Feb 28, 2022O
Not yet recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +2 more
- Portland, OregonOHSU Knight Cancer Institute
2022-03-11
Mar 11, 2022E
Active, not recruiting
- ISS Stage I Plasma Cell Myeloma
- +4 more
- Pembrolizumab
- Radiation Therapy
- Atlanta, GeorgiaEmory University/Winship Cancer Institute
2022-03-02
Mar 2, 2022F
Not yet recruiting
- Plasma Cell Myeloma
- +2 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +4 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-03-01
Mar 1, 2022N
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Laboratory Biomarker Analysis
- +3 more
- Calgary, Alberta, Canada
- +4 more
2022-02-10
Feb 10, 2022C
Active, not recruiting
- Acute Leukemia
- +14 more
- Busulfan
- +10 more
- Duarte, CaliforniaCity of Hope Medical Center
2022-02-17
Feb 17, 2022O
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +58 more
- Abemaciclib
- +55 more
- Portland, OregonOHSU Knight Cancer Institute
2022-02-16
Feb 16, 2022M
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- t(11;14)
- Dexamethasone
- +3 more
- Ann Arbor, Michigan
- +2 more
2022-01-28
Jan 28, 2022M
Active, not recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +13 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +9 more
- Houston, TexasM D Anderson Cancer Center
2022-02-08
Feb 8, 2022M
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Dexamethasone
- +3 more
- Rochester, MinnesotaMayo Clinic in Rochester
2022-02-03
Feb 3, 2022M
Recruiting
- Myelodysplastic Syndrome
- +16 more
- Computed Tomography
- +6 more
- Scottsdale, Arizona
- +2 more
2022-02-03
Feb 3, 2022F
Terminated
- Acute Biphenotypic Leukemia
- +29 more
- Cyclophosphamide
- +9 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-01-24
Jan 24, 2022